Literature DB >> 22796110

Leveraging the cortical cholinergic system to enhance attention.

Elise Demeter1, Martin Sarter.   

Abstract

Attentional impairments are found in a range of neurodegenerative and neuropsychiatric disorders. However, the development of procognitive enhancers to alleviate these impairments has been hindered by a lack of comprehensive hypotheses regarding the circuitry mediating the targeted attentional functions. Here we discuss the role of the cortical cholinergic system in mediating cue detection and attentional control and propose two target mechanisms for cognition enhancers: stimulation of prefrontal α4β2* nicotinic acetylcholine receptors (nAChR) for the enhancement of cue detection and augmentation of tonic acetylcholine levels for the enhancement of attentional control. This article is part of a Special Issue entitled 'Cognitive Enhancers'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796110      PMCID: PMC3445745          DOI: 10.1016/j.neuropharm.2012.06.060

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  162 in total

1.  Evaluation of the information processing and mood effects of a transdermal nicotine patch.

Authors:  D M Warburton; G Mancuso
Journal:  Psychopharmacology (Berl)       Date:  1998-02       Impact factor: 4.530

2.  Cortical input to the basal forebrain.

Authors:  L Zaborszky; R P Gaykema; D J Swanson; W E Cullinan
Journal:  Neuroscience       Date:  1997-08       Impact factor: 3.590

Review 3.  Smoking and attention: a review and reformulation of the stimulus-filter hypothesis.

Authors:  J D Kassel
Journal:  Clin Psychol Rev       Date:  1997

4.  Ultrastructural evidence of amygdalofugal axons terminating on cholinergic cells of the rostral forebrain.

Authors:  L Záborszky; C Léránth; L Heimer
Journal:  Neurosci Lett       Date:  1984-12-21       Impact factor: 3.046

5.  Function of the thalamic reticular complex: the searchlight hypothesis.

Authors:  F Crick
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

Authors:  S L Rogers; M R Farlow; R S Doody; R Mohs; L T Friedhoff
Journal:  Neurology       Date:  1998-01       Impact factor: 9.910

7.  Detection of visual signals by rats: effects of chlordiazepoxide and cholinergic and adrenergic drugs on sustained attention.

Authors:  P J Bushnell; W M Oshiro; B K Padnos
Journal:  Psychopharmacology (Berl)       Date:  1997-12       Impact factor: 4.530

8.  The selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of Alzheimer disease.

Authors:  N C Bodick; W W Offen; H E Shannon; J Satterwhite; R Lucas; R van Lier; S M Paul
Journal:  Alzheimer Dis Assoc Disord       Date:  1997       Impact factor: 2.703

9.  Effects of scopolamine and nicotine on human rapid information processing performance.

Authors:  K Wesnes; D M Warburton
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

10.  Psychophysiological dysfunctions in the developmental course of schizophrenic disorders.

Authors:  M E Dawson; K H Nuechterlein
Journal:  Schizophr Bull       Date:  1984       Impact factor: 9.306

View more
  26 in total

1.  Neurobiological impact of nicotinic acetylcholine receptor agonists: an activation likelihood estimation meta-analysis of pharmacologic neuroimaging studies.

Authors:  Matthew T Sutherland; Kimberly L Ray; Michael C Riedel; Julio A Yanes; Elliot A Stein; Angela R Laird
Journal:  Biol Psychiatry       Date:  2015-01-07       Impact factor: 13.382

Review 2.  Recent theoretical, neural, and clinical advances in sustained attention research.

Authors:  Francesca C Fortenbaugh; Joseph DeGutis; Michael Esterman
Journal:  Ann N Y Acad Sci       Date:  2017-03-05       Impact factor: 5.691

Review 3.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

4.  Effect of acupuncture-like stimulation on cortical cerebral blood flow in aged rats.

Authors:  Sae Uchida; Fusako Kagitani
Journal:  J Physiol Sci       Date:  2014-10-10       Impact factor: 2.781

5.  Selective potentiation of (α4)3(β2)2 nicotinic acetylcholine receptors augments amplitudes of prefrontal acetylcholine- and nicotine-evoked glutamatergic transients in rats.

Authors:  Morten Grupe; Giovanna Paolone; Anders A Jensen; Karin Sandager-Nielsen; Martin Sarter; Morten Grunnet
Journal:  Biochem Pharmacol       Date:  2013-09-16       Impact factor: 5.858

6.  Method for testing sustained attention in touchscreen operant chambers in rats.

Authors:  Brittany Wicks; David E Waxler; Kyle M White; Nina Duncan; Joy Bergmann; Robert D Cole; Vinay Parikh; Debra A Bangasser
Journal:  J Neurosci Methods       Date:  2016-12-08       Impact factor: 2.390

7.  Neuronal effects of nicotine during auditory selective attention.

Authors:  Jason Smucny; Ann Olincy; Lindsay S Eichman; Jason R Tregellas
Journal:  Psychopharmacology (Berl)       Date:  2014-12-10       Impact factor: 4.530

Review 8.  Comparative Perspectives on Oxytocin and Vasopressin Receptor Research in Rodents and Primates: Translational Implications.

Authors:  Sara M Freeman; Larry J Young
Journal:  J Neuroendocrinol       Date:  2016-04       Impact factor: 3.627

9.  The impact of cafeteria diet feeding on physiology and anxiety-related behaviour in male and female Sprague-Dawley rats of different ages.

Authors:  Wiebke Warneke; Susanne Klaus; Heidrun Fink; Simon C Langley-Evans; Jörg-Peter Voigt
Journal:  Pharmacol Biochem Behav       Date:  2013-11-21       Impact factor: 3.533

10.  Contributions of β2 subunit-containing nAChRs to chronic nicotine-induced alterations in cognitive flexibility in mice.

Authors:  Robert D Cole; Rachel L Poole; Dawn M Guzman; Thomas J Gould; Vinay Parikh
Journal:  Psychopharmacology (Berl)       Date:  2014-10-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.